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Abstract: Raf kinases and vascular endothelial growth factor receptor (VEGFR) and 
platelet-derived growth factor receptor (PDGFR) tyrosine kinases are potential molecular 
targets for obtaining both anti-tumor cell progression and anti-angiogenesis effects in cancers, 
including hepatocellular carcinoma (HCC). Sorafenib is an oral multi-kinase inhibitor that mainly 
targets Raf kinases and receptor tyrosine kinases associated with angiogenesis (VEGFR-2/-3, 
PDGFR-β). A global randomized controlled trial (RCT) of sorafenib versus placebo con-
ducted in patients with advanced HCC demonstrated the beneﬁ  cial effects of the drug on the 
time-to-progression and overall survival. Furthermore, a RCT with a similar design to that of 
the global trial conducted in the Asia-Paciﬁ  c region also demonstrated the efﬁ  cacy of the drug. 
The most common treatment-related adverse events of sorafenib were found to be diarrhea, 
fatigue, and skin toxicity, namely, hand-foot syndromes and rash. Based on the results of the 
RCTs, sorafenib has been established as a standard agent for systemic chemotherapy in HCC 
patients with metastatic disease or transcatheter arterial chemoembolization (TACE)-refractory 
disease who are not suitable candidates for local treatments. The efﬁ  cacy and safety of sorafenib 
in patients with moderate liver dysfunction have not been conﬁ  rmed to date and more data are 
needed. Development of new therapeutic methods is needed for the treatment of advanced HCC 
in the future; clinical trials of sorafenib-based combination therapy, second-line therapy after 
sorafenib failure, and adjuvant therapy after local treatments are warranted in HCC patients.
Keywords: hepatocellular carcinoma, sorafenib, raf kinase, vascular endothelial growth factor 
receptor, platelet-derived growth factor receptor
Introduction
Recently, some growth factors and various signal transduction pathways have been 
identiﬁ  ed, and various molecular-targeted agents have being tried for the treatment of 
various tumors, including hepatocellular carcinoma (HCC). These signal transduction 
pathways control the processes of cell proliferation and survival, and also special-
ized functions such as angiogenesis. Dysregulated signaling pathways contribute to 
malignant transformation in human cells. Sorafenib is a small-molecule multi-kinase 
inhibitor that inhibits kinases such as Raf kinase, vascular endothelial growth factor 
receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR)-β tyrosine 
kinases (Wilhelm et al 2004). It inhibits tumor-cell proliferation and angiogenesis and 
increases the rate of apoptosis in a wide range of tumor models (Gollob et al 2006; 
Liu et al 2006; Wilhelm et al 2006; Chang et al 2007).
HCC is the ﬁ  fth most common malignancy worldwide, with approximately 500,000 
new cases diagnosed each year (Parkin et al 2005). Most patients with HCC have 
chronic liver disease, especially liver cirrhosis, which is mainly the result of hepatitis 
virus infection. However, there are clearly deﬁ  ned differences in the etiology of HCC 
among different geographic regions. Hepatitis B virus (HBV) infection is very common 
in East and South-East Asia and Africa; more than 80% HCC patients in these countries 
have HBV infection (McGlynn et al 2001). On the other hand, hepatitis C virus (HCV) Biologics: Targets & Therapy 2008:2(4) 780
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is more common in Japan, and HCV antibody is observed in 
72% of HCC patients in Japan (Ikai et al 2005). The incidence 
of HCV infection is also increasing in the US and Europe, as 
is the incidence of HCC (El-Serag and Mason 1999). Various 
treatment modalities such as surgery, ablation, transcatheter 
arterial chemoembolization (TACE), and liver transplanta-
tion, are available as local therapeutic approaches for HCC. 
Despite the efﬁ  cacy of local therapies, patients frequently 
develop recurrence or disease progression after these treat-
ments. These patients are then offered systemic treatment 
including chemotherapy. However, although response rates 
of 10% to 20% have been reported, the survival beneﬁ  t of 
chemotherapy has never been conﬁ  rmed, either for single-
agent or combination chemotherapy, in these patients.
A phase III, double-blind, placebo-controlled trial of 
sorafenib showed survival beneﬁ  t in patients with advanced 
HCC in 2007 (Llovet et al 2008). As a result, sorafenib has 
been established as a standard agent for systemic chemo-
therapy in patients of HCC. In this paper, the mechanism 
of action of sorafenib and clinical trials of sorafenib for the 
treatment of HCC are reviewed, and future directions for the 
use of this drug are discussed.
Mechanism of action of sorafenib
Many of the processes involved in tumor progression, such 
as cell proliferation, invasion, metastasis and inhibition 
of apoptosis, are mediated by signaling pathways triggered 
by activated receptor tyrosine kinases. Ras functions down-
stream of several receptor tyrosine kinases, and activation of 
Ras signaling pathways is an important mechanism underlying 
the development of human cancer. Ras regulates several 
pathways that synergistically induce cellular transformation, 
including the Raf/mitogen-activated protein kinase (MAPK) 
kinase (MEK)/extracellular signal-regulated kinase (ERK) cas-
cade (Hackel et al 1999; Woodburn 1999; Wilhelm et al 2004). 
The Raf kinases are serine/threonine protein kinases that func-
tion in this pathway as downstream effector molecules of Ras 
(El-Serag and Mason 1999; Wilhelm et al 2004; Llovet et al 
2008). The Raf kinase family is composed of three members, 
namely, A-Raf, B-Raf and Raf-1. Mutations of B-Raf have 
been identiﬁ  ed in various human tumors, such as malignant 
melanomas, colorectal cancer and thyroid papillary cancers 
(Davies et al 2002; Kimura et al 2003). Previous studies have 
reported observing Raf-1 hyperactivation in 6 of 11 (55%) 
renal cell carcinoma (RCC) tumors and all of 30 HCC tumors 
(Oka et al 1995; Hwang et al 2004). Solid tumors aberrantly 
secrete many different growth factors and cytokines, including 
VEGF and PDGF-β. The binding of these growth factors to 
receptors on the surface of endothelial cells activates the 
Raf/MEK/ERK pathways, which results in the induction 
of angiogenesis and lymphangiogenesis (Hood et al 2002). 
Thus, the Ras/Raf signaling pathway is an important mediator 
of tumor cell proliferation and angiogenesis in various solid 
tumors including HCC. Raf kinases and the VEGFR and 
PDGFR tyrosine kinases are potential molecular treatment 
targets for obtaining both antitumor cell progression and 
antiangiogenesis effects.
In order to discover novel therapies targeting the Ras/Raf/
MEK/ERK pathway, screening for Raf-1 kinase inhibitory 
activity was initiated in 1995 by Bayer and Onyx (Figure 1) 
(Wilhelm et al 2006). The ﬁ  rst compound generated, 3-thienyl 
urea, demonstrated Raf1 IC50 (half maximal inhibitory 
concentration) of 17 μmol, and ﬁ  nally sorafenib achieved IC50 
of 6 nmol (Table 1) (Wilhelm et al 2004; Wilhelm et al 2006). 
The chemical name of sorafenib is N-(3-triﬂ  uoromethyl-
4-chlorophenyl)-N’-(4-(2-methylcarbamoyl pyridin-4-yl) 
oxyphenyl) urea, and the structural formula is shown in 
Figure 1. Sorafenib was also shown to potently inhibit the 
wild-type-Raf, and oncogenic b-raf V600E serine/threonine 
kinase, pro-angiogenic receptor tyrosine kinases, c-kit, and 
Flt-3 in vitro (Table 1) (Wilhelm et al 2006).
The anti-tumor efﬁ  cacy and mechanism of action of 
sorafenib was investigated in vitro on PLC/PRF/5 and HepG2 
HCC cells and in vivo on PLC/PRF/5 human tumor xenografts 
in severe combined immunodeﬁ  cient mice (Liu et al 2006). 
Sorafenib inhibited the phosphorylation of MEK and ERK 
and down-regulated cyclin D1 levels in these two cell lines. 
Furthermore, sorafenib reduced the phosphorylation level of 
eIF4E and down-regulated the anti-apoptotic protein Mcl-1 in 
a MEK/ERK-independent manner. Sorafenib demonstrated 
dose-dependent tumor growth inhibition of implanted PLC/
PRF/5 tumor xenografts (Liu et al 2006). The in vivo anti-
tumor activity of sorafenib correlated with the inhibition of 
MAPK signaling, which is indicative of Raf kinase inhibition, 
and inhibition of tumor microvessel area as measured by the 
reduction in CD34 staining (Liu et al 2006). These experi-
ments showed that the anti-tumor activity of sorafenib was 
attributed to inhibition of tumor angiogenesis of VEGFR and 
PDGFR and direct effects on tumor cell proliferation/survival 
of Raf kinase signaling-dependent and signaling-independent 
mechanisms (Figure 2).
Systemic chemotherapy
for hepatocellular carcinoma
Systemic chemotherapy is applied for patients with advanced 
HCC who are not suitable candidates for local treatments, Biologics: Targets & Therapy 2008:2(4) 781
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eg, those with distant metastasis and/or macrovascular 
invasion (Bruix and Sherman 2005). Refractoriness to 
TACE is also considered as an indication for systemic 
chemotherapy. Various studies on chemotherapy for HCC 
have indicated that anthracycline anti-tumor antibiotic 
agents, such as doxorubicin and mitoxantrone, constitute 
the basis for chemotherapy in cases of HCC (Lai et al 1988; 
Colleoni et al 1992). Furthermore, cisplatin and/or ﬂ  uoro-
uracil are the agents most commonly used in combination 
chemotherapy for HCC (Leung et al 1999; Boucher et al 
2002; Patt et al 2003; Ikeda et al 2005). The response rates 
to combination chemotherapies, including ﬂ  uorouracil/mito-
xantrone/cisplatin (FMP), epirubicin/cisplatin/ﬂ  uorouracil 
(ECF) and cisplatin/interferon α-2b/doxorubicin/ﬂ  uoro-
uracil (PIAF), have been reported to range from 14% to 
26%, with the median overall survival (OS) ranging from 
8.9 to 11.6 months. Doxorubicin has been considered as a 
referential arm in randomized clinical trials for HCC based 
on the results of a comparative trial between doxorubicin 
and supportive treatment (Lai et al 1988). Despite phase III 
trials indicating better responses to combination chemo-
therapy than to doxorubicin monotherapy, no standard 
chemotherapy has yet been established that can clearly 
prolong the survival in advanced HCC patients; eg, a recent 
phase III trial of doxorubicin versus PIAF failed to show 
any survival beneﬁ  t of either drug (response rate: 10.5% 
for doxorubicin and 20.9% for PIAF, p = 0.058; median 
OS: 6.8 months for doxorubicin and 8.7 months for PIAF, 
p = 0.83) (Yeo et al 2005). Thus, no standard regimen has 
been identiﬁ  ed by large prospective clinical trials conducted 
until 2007, which can clearly prolong the survival in patients 
with advanced HCC.
Rationale for use and clinical
trials of sorafenib for hepatocellular 
carcinoma
Hepatocarcinogenesis is a multi-step process, slowly 
unfolding on a background of chronic liver disease, most 
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Figure 1 Chemical structural formulas of compounds inhibiting Raf1 and sorafenib.  Adapted by permission from Macmillan Publishers Ltd: Nat Rev Drug Discov, 5:835–44. © 2006.Biologics: Targets & Therapy 2008:2(4) 782
Furuse
often chronic hepatitis and cirrhosis. Recent insights into 
the biology of HCC suggest that certain signaling pathways 
such as the PI3K/Akt/mTOR, Ras/Raf/MEK/ERK and 
Wnt/β-catenin pathways mediated by EGFR and angiogenic 
signaling pathways mediated by VEGFR and PDGFR play 
important roles in the development of HCC by promoting 
cell growth and survival (Avila et al 2006). Some studies 
have demonstrated the important roles played by MAPK/
ERK activation in the multi-step carcinogenetic process 
involved in human HCC, especially in the progression of 
HCC (Schmidt et al 1997; Ito et al 1998). Overexpression of 
phosphorylated MEK1/2 and MAPK in HCC cell lines was 
found to enhance tumor growth and survival by preventing 
apoptosis (Huynh et al 2003). HCC is highly related to HBV 
and HCV infection, and a relationship between expression 
of Raf and HCV/HBV infection has been demonstrated. 
Giambartolomei et al (2001) reported that the ability of HCV 
core proteins to directly activate the MAP kinase cascade, 
especially Raf-1, and to prolong its activity in response to 
mitogenic stimuli may contribute to the neoplastic transfor-
mation of HCV infected liver cells. Chen and Siddiqui (2007) 
reported that HBV X protein (HBx) plays a crucial role in 
the viral life cycle and contributes to the onset of HCC. HBx 
caused mitochondrial translocation of Raf-1 kinase either 
alone or in the context of whole-viral-genome transfections. 
HCC is generally hypervascular and contains rich tumor 
vascularity, and VEGF, which is related to angiogenesis, is 
one of the important factors involved in the angiogenesis in 
HCC (Miura et al 1997; Yamaguchi et al 1998). Moreover, 
VEGF promotes HCC development and metastasis, and 
the serum VEGF level has been reported as a signiﬁ  cant 
independent prognostic factor in patients with HCC (Chao 
et al 2003; Poon et al 2004). Thus, the Raf/MEK/ERK 
pathway and angiogenic-signaling pathways mediated 
by VEGFR and PDGFR are potent molecular targets in 
HCC therapy.
Sorafenib is an oral multi-kinase inhibitor that mainly 
targets Raf kinases and receptor tyrosine kinases associ-
ated with angiogenesis (VEGFR-2/-3, PDGFR-β). In a 
phase I study of sorafenib conducted in 69 patients with 
solid malignant tumors, diarrhea was the most commonly 
encountered treatment-related adverse event and the dose-
limiting toxicities were diarrhea, fatigue, and skin toxicities, 
namely, hand-foot syndromes and rash (Strumberg et al 
2005). The maximum-tolerated dose was found to be 400 mg 
bid continuous and the recommended dose for future studies 
was also determined to be 400 mg bid continuous (Strumberg 
et al 2005). In regard to the efﬁ  cacy, a partial response (PR) 
was observed in only one of 45 patients treated continu-
ously with sorafenib at doses of 100 mg bid, who was a 
patient HCC treated with the drug at 400 mg bid continuous 
(Strumberg et al 2005). In this phase I study, 6 HCC patients 
were assessable for efﬁ  cacy, of which one showed PR, 4 had 
stable disease (SD), and 1 showed progressive disease (PD) 
(Strumberg et al 2005). Based on these preclinical results 
and the results of the phase I study of sorafenib, a phase II 
study was performed in 137 patients with advanced HCC 
(Abou-Alfa et al 2006). Although the response rate was 
low, that is, 2.2%, the time-to progression (TTP) and OS 
were promising; the median TTP was 4.2 months and the 
median OS was 9.2 months (Table 2). The grade 3/4 drug-
related toxicities included fatigue (9.5%), diarrhea (8.0%), 
and hand – foot skin reactions (5.1%), all of which were 
manageable. In this phase II study, the relationship between 
the phosphorylated ERK levels in the tumor cells and the 
efﬁ  cacy was examined, and no signiﬁ  cant difference was 
found in the TTP between patients with higher staining 
intensity of phosphorylated ERK in the tumor cells and those 
with a lower staining intensity (Abou-Alfa et al 2006).
Based on these results, a large randomized controlled 
trial (RCT) of sorafenib versus placebo (the SHARP trial) 
was conducted in patients with advanced HCC (Llovet 
et al 2008). Six hundred two patients were randomized 
into 2 arms, the sorafenib arm and the placebo arm (Table 3). 
The TTP was 5.5 months for sorafenib and 2.8 months 
for placebo, and the hazard ratio in the sorafenib arm 
was 0.58 (95% CI: 0.45–0.74; p  0.001). The median 
OS was 10.7 months for sorafenib and 7.9 months for 
Table 1 In vitro inhibitory profile of sorafenib. Adapted by 
permission from Macmillan Publishers Ltd: Nat Rev Drug Discov, 
5:835–44. © 2006
Kinase target IC50 value (nmol/L)
Raf-1 6
BRAF wild-type 22
Oncogenic b-raf V600E 38
VEGFR-1 26
VEGFR-2 90
Murine VEGR-3 20
Murine PDGFR 57
Flt-3 33
p38 38
c-Kit 68
FGFR-1 580
ERK-1, MEK-1, EGFR, HER-2/neu, 
IGFR-1, c-met, PKA, PKB, CDK1/
cyclin B, pim-1, PKCα, PKCγ
10,000Biologics: Targets & Therapy 2008:2(4) 783
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placebo, and the hazard ratio for OS in the sorafenib arm was 
0.69 (95% CI: 0.55–0.87; p  0.001) (Llovet et al 2008). 
This trial demonstrated a statistically signiﬁ  cant improvement 
not only in the status of disease progression, but also 
in the survival of the patients in the sorafenib arm. The 
most frequently encountered drug-related serious adverse 
events were hand-hoot skin reaction, diarrhea and weight 
loss (Table 4). Thus, sorafenib is the first systemic 
chemotherapeutic agent to prolong survival in patients with 
advanced HCC.
Clinical concerns related to the use
of sorafenib in hepatocellular 
carcinoma
In the SHARP trial, approximately 90% of the patients 
enrolled were from Europe or Australia (Table 3). The dif-
ference in the efﬁ  cacy and safety was a concern in relation to 
the application of sorafenib as a global standard therapeutic 
agent for advanced HCC, as the etiology and treatment 
strategies of HCC vary among regions in the world (Bruix 
et al 2001; Bruix and Sherman 2005; Ikai et al 2005; Kudo 
and Okanoue 2007). Therefore, to conﬁ  rm the efﬁ  cacy and 
safety of the drug in Asian populations, a RCT of sorafenib 
was conducted in the Asia-Paciﬁ  c region (the Asia-Paciﬁ  c 
trial) (Cheng et al 2008). The dose of sorafenib was the same 
as that in the SHARP trial, namely, 400 mg bid continuous, 
and patients were randomized 2:1 to sorafenib or placebo 
(Table 3). The most frequently reported drug-related seri-
ous adverse events were hand-hoot skin reactions, diarrhea, 
hyperbilirubinemia and fatigue, similar to those observed in 
the SHARP trial (Table 4). The median OS of the primary 
endpoint was 6.5 months for sorafenib and 4.2 months for 
placebo, and the hazard ratio for OS in the sorafenib arm was 
0.67 (95% CI: 0.49–0.93; p = 0.0155) (Cheng et al 2008). The 
TTP was 2.8 months in the sorafenib arm and 1.4 months in 
the placebo arm, and the hazard ratio in the sorafenib arm 
was 0.58 (95% CI: 0.42–0.80; p  = 0.0007). The etiology of 
HCC in the Asia-Paciﬁ  c trial was different from that in the 
SHARP trial; HBV infection was observed in more than 70% 
of the patients in Asia (Table 3). However, the hazard ratios 
of OS and TTP were very similar to those in the SHARP 
trial, which indicated that efﬁ  cacy is expected regardless of 
the difference in the etiology. Despite the equivalent hazard 
ratio for OS and TTP in the two RCTs, median OS and TTP 
were very poor in the Asia-Paciﬁ  c trial compared with those 
in the SHARP trial, phase II and Japanese phase I studies. 
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Figure 2 Mechanism of action of sorafenib. Sorafenib exerts a dual anticancer effect on the tumor and tumor vasculature by inhibiting Raf kinases including Raf-1 as well 
as the receptor tyrosine kinases vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR3, platelet-derived growth factor receptor (PDGFR), etc. Reproduced with 
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This disadvantage was due to the difference in the patient 
characteristics, such as the poorer performance status (69% 
of ECOG PS [Eastern Cooperative Oncology Group Per-
formance Status]) and more advanced stage of the cancer 
(96% of BCLC [Barcelona Clinic Liver Cancer staging clas-
siﬁ  cation] stage C, 52% of lung metastases). In conclusion, 
from the SHARP trial and the Asia-Paciﬁ  c trial, while the 
difference in the etiology of HCC is not of critical concern, 
the advanced stage of the disease at diagnosis and a poor PS 
may be among the main reasons for the poor outcomes of 
sorafenib treatment.
There is another important issue of whether sorafenib 
can be used in patients with Child-Pugh class B disease, 
or moderate liver dysfunction, because patients enrolled 
in the SHARP trial were limited to those with good 
liver function classiﬁ  ed into Child-Pugh A. In Japan, a 
phase I study of sorafenib was conducted to investigate 
the pharmacokinetics, safety and efﬁ  cacy of the drug in 
Japanese patients with advanced HCC; there was an equal 
number of patients with Child-Pugh A and B disease 
(Furuse et al 2008). The results revealed a safety proﬁ  le 
similar to that in the RCTs of sorafenib and the same 
recommended dose of 400 mg bid. The response rate was 
3.7%, and the median TTP and OS were 4.9 months and 
15.6 months, respectively (Table 2) (Furuse et al 2008). In 
regard to the difference in the pharmacokinetics between 
patients with Child-Pugh A and B, although both areas 
under the concentration – time curve for 0 to 12 h and 
the maximal concentration at steady state were slightly 
lower in the Child – Pugh class B patients than in the 
Child-Pugh class A patients. There was no major differ-
ence in the incidence and grade of drug-related adverse 
Table 2 Phase II study of sorafenib in the US and Europe and phase I study in Japan
Study Phase II study 
(Abou-Alfa et al 2006)
Japanese Phase I study
(Furuse et al 2008)
n 137 27
Child-Pugh A/B 98/38 13/14
Dose 400 mg bid 200, 400 mg bid
Partial response 3 (2.2%) 1 (3.7%)
Stable disease 54 (39.4%) 21 (77.8%)
Disease control rate 41.6% 81.5%
Progressive disease 48 (35.0%) 3 (11.1%)
Not assessed 32 (23.4%) 2 (7.4%)
Median time to progression 4.2 mo 4.9 mo
Median overall survival 9.2 mo 15.6 mo
Table 3 Patient background in randomized controlled trials of sorafenib versus placebo in the SHARP trial and Asia-Paciﬁ  c trial
SHARP study (Llovet et al 2008) Asia-Paciﬁ  c study (Cheng et al 2008)
Sorafenib Placebo Sorafenib Placebo
N 299 303 150 76
Median age 64.9 66.3 51 52
Male 87% 87% 85% 87%
Region: Europe and Australia 88% 87% – –
HCV/HBV/alcohol 29/19/26% 27/18/26% 71/11/NA% 78/4/NA%
ECOG PS 0/1/2 54/38/8% 54/39/7% 25/69/5% 28/67/5%
BCLC stage B/C 18/82% 17/83% 4/96% 4/96%
Macroscopic vascular invasion 36% 41% 36% 34%
Extrahepatic spread 53% 50% 69% 68%
 Lymph  nodes 30% 21% 31% 34%
 Lung 22% 19% 52% 45%
Child-Pugh A 95% 98% 97% 97%
Abbreviations: HCV, hepatitis C virus; HBV, hepatitis B virus; PS, performance status; BCLC stage, barcelona clinic liver cancer staging classiﬁ  cation; ECOG PS, eastern cooperative 
oncology group performance status.Biologics: Targets & Therapy 2008:2(4) 785
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events between the Child-Pugh class A and B groups, but 
hypertension, hand – foot skin reactions, and rash were 
more frequently observed in the Child-Pugh class B group 
than in the Child-Pugh class A group. In a phase I study 
of sorafenib for solid tumors and hematologic malignan-
cies in patients with hepatic or renal dysfunction, it was 
observed that 9 out of 12 events in patients with liver 
dysfunction as the dose-limiting toxicity were increase in 
the serum bilirubin level (Miller et al 2007).
Comparison of the efficacy and safety between 
Child-Pugh class A and B patients was also examined in 
a phase II study in HCC patients (Abou-Alfa et al 2008a). 
The pharmacokinetic and overall toxic profiles were 
similar in both groups. However, adverse events related 
to liver cirrhosis, such as bilirubin increase, ascites and 
encephalopathy, occurred more frequently in Child-Pugh 
class B than class A patients. Furthermore, the TTP and OS 
appeared to be worse in the Child-Pugh class B patients than 
in the Child-Pugh class A patients. The Child-Pugh class B 
group is generally heterogeneous with scores ranging from 
7 to 9 (Pugh et al 1973). The indications of sorafenib in 
Child-Pugh B patients should be carefully considered and 
more data are required to conﬁ  rm the safety and efﬁ  cacy of 
sorafenib in practice and in clinical trials in these patients 
in the future.
Conclusions and future directions
of chemotherapy for HCC
In patients with advanced HCC, the survival beneﬁ  t of 
sorafenib has been demonstrated in a RCT for the ﬁ  rst time, 
and the drug has already been approved for the treatment 
of HCC. However, the efficacy remains moderate, and 
Table 4 Severe drug-related serious adverse events in the SHARP trial and Asia-Paciﬁ  c trial
SHARP study (Llovet et al 2008) Asia-Paciﬁ  c study (Cheng et al 2008)
Grade 3/4 toxicity Sorafenib Placebo p-value Sorafenib Placebo
Hand-foot skin reaction 8% 1% 0.001 10% 0%
Diarrhea 8% 2% 0.001 6% 0%
Hyperbilirubinemia – – – 3% 3%
Fatigue 4% 4% 13 % 1 %
Weight loss 2% 0% 0.03 – –
Hypertension 2% 1% 0.28 – –
Total 13% 9% – 9% 1%
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other promising agents need to be developed for further 
prolonging the survival in HCC patients. Sunitinib, an oral, 
multitargeted tyrosine kinase inhibitor, has shown promis-
ing activity against HCC in phase II studies, with a median 
progression-free survival (PFS) of about 4 months and 
median OS of about 10 months (Faivre et al 2007; Zhu et al 
2008). Bevacizumab, a recombinant, humanized monoclonal 
antibody that targets VEGF, has been investigated in phase 
II studies of bevacizumab alone or the agent administered in 
combination with erlotinib (Thomas et al 2007; Siegel et al 
2008). The response rates in these studies were moderate, 
ranging from 10% to 20%. The median PFS achieved was 
very promising, ranging from 5.3 to 9.0 months, especially 
for the combination of bevacizumab and erlotinib. On the 
other hand, enhancement of the efﬁ  cacy of sorafenib by its 
use in combination regimens has also been investigated, 
eg, a randomized phase II study of sorafenib plus doxoru-
bicin showed encouraging outcomes in terms of the TTP 
and OS, with a median TTP of 8.5 months and median 
OS of 14.0 months (Abou-Alfa et al 2008b). Some agents 
selectively targeting VEGFR or mTOR are currently being 
investigated for various solid tumors, and are eventually 
expected to also be applied for the treatment of HCC.
There would be various ways in development of new 
systemic therapeutic regimen after the establishment of 
standard therapy using sorafenib. One of them is the use 
of sorafenib-based combined therapy as ﬁ  rst-line therapy. 
Combination with cytotoxic agents would be investigated, 
but the hepatic toxicity may be a concern, as previous many 
cytotoxic chemotherapeutic regimens failed to prolong the 
survival in HCC patients. Since various cellular signaling 
pathways are implicated in hepatocarcinogenesis, combi-
nation with other molecular-targeted agents with different 
mechanisms of action would be promising, but the toxicity 
may again be a concern. Another issue of interest is second-
line treatment in patients with sorafenib-refractory disease. 
In HCC patients with good liver function, prolonged survival 
would be expected even in cases showing disease progression 
after sorafenib treatment; eg, a survival time of 5.2 months 
was obtained after disease progression in the SHARP trial. 
In a Japanese phase I study of sorafenib, despite the median 
TTP being only 4.9 months, the median OS was relatively 
good, at 15.6 months. Various treatments might inﬂ  uence the 
survival after sorafenib failure. Therefore, it would be pos-
sible to develop post-sorafenib treatments, and second-line 
treatment is important to prolong the survival.
Although sorafenib is the ﬁ  rst agent shown to improve the 
survival of patients with advanced HCC and is generally well 
tolerated, diverse results in terms of the safety and the efﬁ  cacy 
have been obtained; some patients show severe toxicities, such 
as hand – foot skin reactions, and some patients show very 
short survival. Population differences in gene expressions 
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could contribute to the differences in the susceptibility of HCC 
to drug treatments. Genome-wide association studies for local 
or distant genetic variants correlated with the differentially 
expressed genes led to identiﬁ  cation of signiﬁ  cant associations 
with one or more single-nucleotide polymorphisms (SNPs) 
(Stranger et al 2007; Zhang et al 2008). In order to identify 
patients who will beneﬁ  t from sorafenib, attempts must be 
made, by pharmacogenomic studies, to identify biomarkers 
and/or SNPs that would predict the efﬁ  cacy, toxicity and 
resistance to sorafenib.
Sorafenib is currently established as a drug for prolonging 
the survival in HCC patients with metastatic disease or 
TACE-refractory disease who are not suitable candidates 
for local treatments. The FDA approved sorafenib for use in 
the treatment of patients with unresectable HCC. Therefore, 
it can also be used in combination with local therapies, 
such as local ablation therapy or TACE. Although interest 
has also been focused on the use of the drug as adjuvant 
treatment after local treatments like surgical resection, 
ablation therapy and TACE, no adjuvant treatments after 
local therapies have been established to date in HCC. In 
Japan and Korea, a large RCT of sorafenib as post-TACE 
adjuvant therapy is ongoing. Rather than gross advanced 
tumors, tiny residual tumors after these local treatments 
seem to be more effectively treated by cytostatic agents 
like sorafenib. Furthermore, there is the possibility of 
preventing progression from precancerous lesions like 
dysplastic nodules associated with cirrhotic liver to cancer 
using growth factor inhibitors. In the future, investigation 
of sorafenib or other molecular-targeted therapies is also 
expected in the adjuvant or prophylactic setting.
Disclosures
The author has no conﬂ  icts of interest to disclose.
References
Abou-Alfa G, Johnson P, Knox J, et al. 2008b. Preliminary results from a 
Phase II, randomized, double-blind study of sorafenib plus doxorubicin 
versus placebo plus doxorubicin in patients with advanced hepatocellular 
carcinoma. Eur J Cancer, 5(Suppl):259, #3500.
Abou-Alfa GK, Amadori D, Santoro A, et al. 2008a. Is sorafenib (S) safe 
and effective in patients (pts) with hepatocellular carcinoma (HCC) 
and Child-Pugh B (CPB) cirrhosis? Proc Am Soc Clin Oncol, 26: 217s, 
#4518.
Abou-Alfa GK, Schwartz L, Ricci S, et al. 2006. Phase II study of sorafenib 
in patients with advanced hepatocellular carcinoma. J Clin Oncol, 
24:4293–300.
Avila MA, Berasain C, Sangro B, et al. 2006. New therapies for hepatocel-
lular carcinoma. Oncogene, 25:3866–84.
Boucher E, Corbinais S, Brissot P, et al. 2002. Treatment of hepatocellular 
carcinoma (HCC) with systemic chemotherapy combining epirubicin, 
cisplatinum and infusional 5-ﬂ  uorouracil (ECF regimen). Cancer 
Chemother Pharmacol, 50:305–8.
Bruix J, Sherman M, Llovet JM, et al. 2001. Clinical management of 
hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL 
conference. European Association for the Study of the Liver. J Hepatol, 
35:421–30.
Bruix J, Sherman M. 2005. Management of hepatocellular carcinoma. 
Hepatology, 42:1208–36.
Chang YS, Adnane J, Trail PA, et al. 2007. Sorafenib (BAY 43-9006) inhibits 
tumor growth and vascularization and induces tumor apoptosis and hypoxia 
in RCC xenograft models. Cancer Chemother Pharmacol, 59:561–74.
Chao Y, Li CP, Chau GY, et al. 2003. Prognostic signiﬁ  cance of vascular 
endothelial growth factor, basic ﬁ  broblast growth factor, and angiogenin 
in patients with resectable hepatocellular carcinoma after surgery. Ann 
Surg Oncol, 10:355–62.
Chen J, Siddiqui A. 2007. Hepatitis B virus X protein stimulates the mitochon-
drial translocation of Raf-1 via oxidative stress. J Virol, 81:6757–60.
Cheng AL, Kang Y, Chen Z, et al. 2008. Randomized phase III trial of 
sorafenib versus placebo in Asian patients with advanced hepatocellular 
carcinoma. Proc Am Soc Clin Oncol, 26:215s, #4509.
Colleoni M, Nole F, Di Bartolomeo M, et al. 1992. Mitoxantrone in patients 
affected by hepatocellular carcinoma with unfavorable prognostic 
factors. Oncology, 49:139–42.
Davies H, Bignell GR, Cox C, et al. 2002. Mutations of the BRAF gene in 
human cancer. Nature, 417:949–54.
El-Serag HB, Mason AC. 1999. Rising incidence of hepatocellular 
carcinoma in the United States. N Engl J Med, 340:745–50.
Faivre SJ, Raymond E, Douillard J, et al. 2007. Assessment of safety 
and drug-induced tumor necrosis with sunitinib in patients (pts) with 
unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol, 
25:149s, #3546.
Furuse J, Ishii H, Nakachi K, et al. 2008. Phase I study of sorafenib 
in Japanese patients with hepatocellular carcinoma. Cancer Sci, 
99:159–65.
Giambartolomei S, Covone F, Levrero M, et al. 2001. Sustained activa-
tion of the Raf/MEK/Erk pathway in response to EGF in stable cell 
lines expressing the Hepatitis C Virus (HCV) core protein. Oncogene, 
20:2606–10.
Gollob JA, Wilhelm S, Carter C, et al. 2006. Role of Raf kinase in cancer: 
therapeutic potential of targeting the Raf/MEK/ERK signal transduction 
pathway. Semin Oncol, 33:392–406.
Hackel PO, Zwick E, Prenzel N, et al. 1999. Epidermal growth factor 
receptors: critical mediators of multiple receptor pathways. Curr Opin 
Cell Biol, 11:184–9.
Hood JD, Bednarski M, Frausto R, et al. 2002. Tumor regression by targeted 
gene delivery to the neovasculature. Science, 296:2404–7.
Huynh H, Nguyen TT, Chow KH, et al. 2003. Over-expression of the 
mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in 
hepatocellular carcinoma: its role in tumor progression and apoptosis. 
BMC Gastroenterol, 3:19–39.
Hwang YH, Choi JY, Kim S, et al. 2004. Over-expression of c-raf-1 
proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol 
Res, 29:113–21.
Ikai I, Arii S, Ichida T, Okita K, et al. 2005. Report of the 16th follow-up 
survey of primary liver cancer. Hepatol Res, 32:163–72.
Ikeda M, Okusaka T, Ueno H, et al. 2005. A phase II trial of continuous 
infusion of 5-ﬂ  uorouracil, mitoxantrone, and cisplatin for metastatic 
hepatocellular carcinoma. Cancer, 103:756–62.
Ito Y, Sasaki Y, Horimoto M, et al. 1998. Activation of mitogen-activated 
protein kinases/extracellular signal-regulated kinases in human 
hepatocellular carcinoma. Hepatology, 27:951–8.
Kimura ET, Nikiforova MN, Zhu Z, et al. 2003. High prevalence of BRAF 
mutations in thyroid cancer: genetic evidence for constitutive activation 
of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid 
carcinoma. Cancer Res, 63:1454–7.
Kudo M, Okanoue T; Japan Society of Hepatology. 2007. Management of 
hepatocellular carcinoma in Japan: consensus-based clinical practice 
manual proposed by the Japan Society of Hepatology. Oncology, 
72(Suppl 1):2–15.Biologics: Targets & Therapy 2008:2(4) 788
Furuse
Lai CL, Wu PC, Chan GC, et al. 1988. Doxorubicin versus no antitumor 
therapy in inoperable hepatocellular carcinoma. A prospective 
randomized trial. Cancer, 62:479–83.
Leung TW, Patt YZ, Lau WY, et al. 1999. Complete pathological remission 
is possible with systemic combination chemotherapy for inoperable 
hepatocellular carcinoma. Clin Cancer Res, 5:1676–81.
Liu L, Cao Y, Chen C, Zhang X, et al. 2006. Sorafenib blocks the RAF/MEK/
ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis 
in hepatocellular carcinoma model PLC/PRF/5. Cancer Res, 66:11851–8.
Llovet JM, Ricci S, Mazzaferro V, et al. 2008. Sorafenib in advanced 
hepatocellular carcinoma. N Engl J Med, 359:378–90.
McGlynn KA, Tsao L, Hsing AW, et al. 2001. International trends and 
patterns of primary liver cancer. Int J Cancer, 94:290–6.
Miller AA, Murry DJ, Owzar K, et al. 2007. Pharmacokinetic (PK) and phase 
I study of sorafenib (S) for solid tumors and hematologic malignancies 
in patients with hepatic or renal dysfunction (HD or RD): CALGB 
60301. Proc Am Soc Clin Oncol, 25:147s, #3538.
Miura H, Miyazaki T, Kuroda M, et al. 1997. Increased expression of 
vascular endothelial growth factor in human hepatocellular carcinoma. 
J Hepatol, 27:854–61.
Oka H, Chatani Y, Hoshino R, et al. 1995. Constitutive activation 
of mitogen-activated protein (MAP) kinases in human renal cell 
carcinoma. Cancer Res, 55:4182–7.
Parkin DM, Bray F, Ferlay J, et al. 2005. Global cancer statistics, 2002. CA 
Cancer J Clin, 55:74–108.
Patt YZ, Hassan MM, Lozano RD, et al. 2003. Phase II trial of systemic 
continuous ﬂ  uorouracil and subcutaneous recombinant interferon Alfa-2b 
for treatment of hepatocellular carcinoma. J Clin Oncol, 21:421–7.
Poon RT, Ho JW, Tong CS, et al. 2004. Prognostic signiﬁ  cance of serum 
vascular endothelial growth factor and endostatin in patients with 
hepatocellular carcinoma. Br J Surg, 91:1354–60.
Pugh RNH, Murray-Lyon IM, Dawson JL, et al. 1973. Transection of the 
esophagus for bleeding esophageal varices. Br J Surg, 60:646–54.
Schmidt CM, McKillop IH, Cahill PA, et al. 1997. Increased MAPK 
expression and activity in primary human hepatocellular carcinoma. 
Biochem Biophys Res Commun, 236:54–8.
Siegel AB, Cohen EI, Ocean A, et al. 2008. Phase II trial evaluating 
the clinical and biologic effects of bevacizumab in unresectable 
hepatocellular carcinoma. J Clin Oncol, 26:2992–8.
Stranger BE, Nica AC, Forrest MS, et al. 2007. Population genomics of 
human gene expression. Nat Genet, 39:1217–24.
Strumberg D, Richly H, Hilger RA, et al. 2005. Phase I clinical and 
pharmacokinetic study of the Novel Raf kinase and vascular endothelial 
growth factor receptor inhibitor BAY 43–9006 in patients with advanced 
refractory solid tumors. J Clin Oncol, 23:965–72.
Thomas MB, Chadha R, Iwasaki M, et al. 2007. The combination of 
bevacizumab (B) and erlotinib (E) shows signiﬁ  cant biological activity 
in patients with advanced hepatocellular carcinoma (HCC). Proc Am 
Soc Clin Oncol, 25:214s, #4567.
Wilhelm S, Carter C, Lynch M, et al. 2006. Discovery and development 
of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug 
Discov, 5:835–44.
Wilhelm SM, Carter C, Tang L, et al. 2004. BAY 43–9006 exhibits broad 
spectrum oral antitumor activity and targets the RAF/MEK/ERK 
pathway and receptor tyrosine kinases involved in tumor progression 
and angiogenesis. Cancer Res, 64:7099–109.
Woodburn JR. 1999. The epidermal growth factor receptor and its inhibition 
in cancer therapy. Pharmacol Ther, 82:241.
Yamaguchi R, Yano H, Iemura A, et al. 1998. Expression of vascular endo-
thelial growth factor in human hepatocellular carcinoma. Hepatology, 
28:68–77.
Yeo W, Mok TS, Zee B, et al. 2005. A randomized phase III study 
of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/
fluorouracil (PIAF) combination chemotherapy for unresectable 
hepatocellular carcinoma. J Natl Cancer Inst, 97:1532–8.
Zhang W, Duan S, Kistner EO, et al. 2008. Evaluation of genetic variation 
contributing to differences in gene expression between populations. 
Am J Hum Genet, 82:631–40.
Zhu AX, Sahani DV, di Tomaso E, et al. 2008. Sunitinib monotherapy 
in patients with advanced hepatocellular carcinoma (HCC): Insights 
from a multidisciplinary phase II study. Proc Am Soc Clin Oncol, 
26:218s, #4521.